TYRA Tyra Biosciences, Inc.
Financings ·
Tyra Biosciences priced 9,079,000 common shares and pre-funded warrants for 9,078,529 more, expecting about $400.0 million gross at $22.03 a share. The company had $73.8 million of cash at June 30, 2026, and a 2025 net loss of $119.9 million.
Tyra Biosciences has sold the full $150,000,000 under its May 2025 at-the-market agreement and has raised the ceiling to $250,000,000. The filing also shows a 2025 net loss of $119.9 million and cash used in operations of $95.1 million.
Tyra Biosciences is a clinical-stage biotechnology company developing precision medicines for targeted oncology and genetically defined conditions by targeting fibroblast growth factor receptor (FGFR) biology. Its in-house SNÅP platform is used to design oral small molecule product candidates. Its lead program, oral dabogratinib (formerly TYRA-300), is designed to be more selective for FGFR3 than FGFR1, FGFR2 and FGFR4, and is being developed for urothelial cancers and skeletal dysplasia conditions. Initial proof-of-concept results came from the Phase 1 SURF301 study in metastatic urothelial carcinoma, and oral dabogratinib has been administered to over 100 participants across multiple clinical studies. The company is advancing dabogratinib in three Phase 2 trials: SURF303 for low-grade upper tract urothelial carcinoma, SURF302 for intermediate risk non-muscle invasive bladder cancer, and BEACH301 for achondroplasia in children. It calls this its dabogratinib 3x3 strategy and expects to move toward three potential registrational trials if those studies succeed.
| Product or program | What it is | Stage |
|---|---|---|
| oral dabogratinib (formerly TYRA-300) | FGFR3-selective oral small molecule for urothelial cancers and skeletal dysplasia | Phase 2 |
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $102.9 million | $80.1 million |
| Net income (loss) | -$119.9 million | -$86.5 million |
| Cash from operations | -$95.1 million | -$69.8 million |
| Cash and equivalents | $77.4 million | $92.0 million |
Our latest story on this, dated Sep 15, 2026: "Tyra Biosciences prices $400 million offering of shares and pre-funded warrants at $22.03". The story links the filing or release it is based on. Read the story.
Tyra Biosciences, Inc. trades under the ticker TYRA on NASDAQ.
Tyra Biosciences, Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for Tyra Biosciences, Inc. is 1863127. Its filings are on SEC EDGAR.
59,676,939 shares as of 2026-07-31, per the cover page of its 10-Q filed 2026-08-04.
Our directory records Tyra Biosciences, Inc. under United States.
Our directory classifies Tyra Biosciences, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Tyra Biosciences, Inc. is US90240B1061.
aibio.space lists Tyra Biosciences, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Tyra Biosciences is a clinical-stage biotechnology company developing precision medicines for targeted oncology and genetically defined conditions by targeting fibroblast growth factor receptor (FGFR) biology. Its in-house SNÅP platform is used to design oral small molecule product candidates.
oral dabogratinib (formerly TYRA-300): FGFR3-selective oral small molecule for urothelial cancers and skeletal dysplasia Stage: Phase 2.
Tyra Biosciences, Inc. reported a net loss of $119.9 million for the fiscal year ended Dec 31, 2025, and used $95.1 million of cash in operations, per its annual report to the SEC.
$102.9 million in the fiscal year ended Dec 31, 2025, per its annual report.
$73.8 million in cash at Jun 30, 2026, per its 10-Q.
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio